Brought to you by 
Novartis buys immuno-oncology biotech Admune for $258mm
25 Sep 2017
Executive Summary
Novartis AG acquired privately held Admune Therapeutics LLC (cytokine drug candidates for immuno-oncology) for $140mm up front plust $118mm tied to development and commercialization milestones.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com